Key result
Carvedilol therapy improved cardiac function and increased free fatty acid metabolism in a patient with dilated cardiomyopathy and type I CD36 deficiency.
Why the study?
Does carvedilol improve cardiac function and free fatty acid metabolism in a patient with dilated cardiomyopathy and type I CD36 deficiency?
Case Report (n=1)
Does carvedilol improve cardiac function and free fatty acid metabolism in a patient with dilated cardiomyopathy and type I CD36 deficiency?
Carvedilol therapy may improve cardiac function and free fatty acid metabolism in patients with dilated cardiomyopathy and type I CD36 deficiency.
A 27-year-old man diagnosed as having dilated cardiomyopathy (DCM) without myocardial accumulation of 123I-beta-methyl-iodophenylpentadecanoic acid, and he was found to have type I CD36 deficiency. This abnormality of cardiac free fatty acid metabolism was also confirmed by other methods: 18F-fluoro-2-deoxyglucose positron emission tomography, measurements of myocardial respiratory quotient and cardiac fatty acid uptake. Although the type I CD36 deficiency was reconfirmed after 3 months, the abnormal free fatty acid metabolism improved after carvedilol therapy and was accompanied by improved cardiac function. Apart from a cause-and-effect relationship, carvedilol can improve cardiac function and increase free fatty acid metabolism in patients with both DCM and CD36 deficiency.
No takes yet. Share an insight, caveat, or question.
Hirooka et al. (2000) conducted a case report in Dilated cardiomyopathy with type I CD36 deficiency (n=1). Carvedilol was evaluated on Cardiac function and free fatty acid metabolism. Carvedilol therapy improved cardiac function and increased free fatty acid metabolism in a patient with dilated cardiomyopathy and type I CD36 deficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: